Parkinson's disease is a progressive neurological disorder that affects more than a million Americans, with roughly 90,000 new diagnoses each year. While current medicines can ease tremors and stiffness, none can truly halt the disease's advance.
The root cause lies in the brain’s dwindling supply of dopamine, a neurotransmitter essential for smooth movement, mood regulation, and memory. As dopamine‑producing neurons die, patients experience the classic symptoms of tremors, rigid muscles, and slowed motion.
Scientists at Keck Medicine of USC have launched a pioneering clinical study that targets this dopamine deficit head‑on. In the early‑phase trial (identifier NCT06687837), neurosurgeons implant specially engineered stem cells directly into the brain’s movement‑control region.
"If we can restore normal dopamine levels, we may be able to slow disease progression and bring back lost motor abilities," explains Dr. Brian Lee, the study’s principal investigator.
Induced Pluripotent Stem Cells Designed to Produce Dopamine
The therapy relies on induced pluripotent stem cells (iPSCs). Unlike embryonic stem cells, iPSCs are created by reprogramming a patient’s own skin or blood cells back to a versatile, embryonic‑like state. From there, they can be coaxed to become dopamine‑producing neurons.
Dr. Xenos Mason, a neurologist specializing in movement disorders, adds, "These iPSCs reliably mature into dopamine‑secreting cells, giving the brain a fresh source of the neurotransmitter it desperately needs."
Precise Brain Implant and Ongoing Monitoring
During the procedure, Dr. Lee makes a small burr hole in the skull and, guided by real‑time MRI, deposits the cells into the basal ganglia—the hub that orchestrates movement. After surgery, participants are followed for 12‑15 months to assess symptom changes and watch for side effects such as dyskinesia or infection. The study plans to extend observation up to five years.
"Our goal is to develop a technique that repairs motor circuits and dramatically improves quality of life," says Dr. Lee.
The trial involves twelve volunteers with moderate to severe Parkinson’s across three U.S. sites. The stem‑cell product, called RNDP‑001, is manufactured by Kenai Therapeutics, a biotech firm focused on neurological disorders. The FDA has granted the trial fast‑track status to accelerate development.
Disclosure: Dr. Mason has previously received an honorarium from Kenai Therapeutics.